Gene-to-Patient Market
完整報告名稱與涵蓋範圍
Gene-to-Patient Market Size, Share & Trends Analysis Report By Type (Gene Therapy, Gene Editing, Gene Silencing), By Application (Cancer Treatment, Genetic Disorders, Cardiovascular Diseases, Rare Diseases, Infectious Diseases), By End-user (Hospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories), By Technology, By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031
報告摘要
In 2023, the Gene-to-Patient Market worldwide was assessed at USD 134.6 billion. Analysts project it will accelerate to USD 341.4 billion by 2031, at a CAGR of 12.5% spanning 2024 to 2031.
At its core, Gene-to-Patient pertains to The gene-to-patient method intends to diagnose, treat, or prevent genetic diseases by creating and administering gene therapies that correct genetic information within a patient's cells. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the surging emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, underpinned by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene-to-Patient Market Snapshot
Chapter 4. Global Gene-to-Patient Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Gene-to-Patient Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Gene-to-Patient Industry Trends
Chapter 5. Gene-to-Patient Market Segmentation 1: By Application, Estimates & Trend Analysis
5.1. Market Share by Application, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
5.2.1. Cancer Treatment
5.2.2. Genetic Disorders
5.2.3. Cardiovascular Diseases
5.2.4. Rare Diseases
5.2.5. Infectious Diseases
Chapter 6. Gene-to-Patient Market Segmentation 2: By End-User, Estimates & Trend Analysis
6.1. Market Share by End-User, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User:
6.2.1. Hospitals
6.2.2. Research Institutes
6.2.3. Biopharmaceutical Companies
6.2.4. Diagnostic Laboratories
Chapter 7. Gene-to-Patient Market Segmentation 3: By Technology, Estimates & Trend Analysis
7.1. Market Share by Technology, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Technologys:
7.2.1. CRISPR
7.2.2. Viral Vector Technology
7.2.3. Non-Viral Delivery Technology
7.2.4. Antisense Oligonucleotide Technology
Chapter 8. Gene-to-Patient Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share by Type, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Types:
8.2.1. Gene Therapy
8.2.2. Gene Editing
8.2.3. Gene Silencing
Chapter 9. Gene-to-Patient Market Segmentation 5: By Distribution Channel, Estimates & Trend Analysis
9.1. Market Share by Distribution Channel, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channeles:
9.2.1. Direct Sales
9.2.2. Online Sales
9.2.3. Third-party Distributors
Chapter 10. Gene-to-Patient Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Gene-to-Patient Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.2.3. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.2.4. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.2.5. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.2.6. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3. Europe
10.3.1. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.3.3. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.3.4. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.3.5. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.3.6. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024- 2031
10.4.3. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.4.4. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Technology, 2024-2031
10.4.5. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.4.6. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
10.5. Latin America
10.5.1. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.5.3. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.5.4. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.5.5. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.5.6. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.6.3. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.6.4. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.6.5. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.6.6. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Illumina
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Thermo Fisher Scientific
11.2.3. Roche Diagnostics
11.2.4. Qiagen
11.2.5. BioRad Laboratories
11.2.6. Abbott Laboratories
11.2.7. PerkinElmer
11.2.8. Invitae
11.2.9. Myriad Genetics
11.2.10. Guardant Health
11.2.11. Foundation Medicine
11.2.12. Genomic Health
11.2.13. Agilent Technologies
11.2.14. Laboratory Corporation of America (LabCorp)
11.2.15. Exact Sciences
11.2.16. Genscript Biotech Corporation
11.2.17. CRISPR Therapeutics AG
11.2.18. Editas Medicine
11.2.19. Intellia Therapeutics Inc.
11.2.20. Beam Therapeutics Inc.
11.2.21. Caribou Biosciences Inc.
11.2.22. Lonza Group Ltd.
11.2.23. Other Market Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們